Dr. Benson on the Ongoing Research With Immunotherapy in mCRC

Video

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Currently, research with immunotherapy is limited to patients with microsatellite instability—high (MSI–H) tumors, says Benson. Studies have shown the activity of pembrolizumab (Keytruda) and nivolumab (Opdivo), as well as the combination of nivolumab and ipilimumab (Yervoy). Whether checkpoint inhibitors should be used alone or in combination is an area of active investigation, explains Benson. A patient with MSI-H mCRC has a worse prognosis. If the patient progressed on frontline therapy, a combination therapy could induce a quicker response compared with single-agent therapy.

Investigators are also evaluating immunotherapy in the adjuvant setting, says Benson. The challenge is making the approach effective for the majority of patients who are not MSI-H. Potential strategies to overcome the limitations of single-agent immunotherapy in patients with microsatellite stable disease population include combinations of immunotherapy with radiation, liver-directed therapy, chemotherapy, targeted agents, and vaccines, says Benson.

Related Videos
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD